mRNA-based Investigational Pandemic H5 Influenza Vaccine
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 06, 2026
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
(clinicaltrials.gov)
- P1/2 | N=991 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed | Trial primary completion date: Aug 2025 ➔ Jan 2026
Trial completion • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases
May 22, 2025
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
(clinicaltrials.gov)
- P1/2 | N=996 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: May 2025 ➔ Jan 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2025
Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases
April 24, 2024
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
(clinicaltrials.gov)
- P1/2 | N=1080 | Recruiting | Sponsor: GlaxoSmithKline
New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases
1 to 3
Of
3
Go to page
1